The Albumin-bilirubin Grade as Prognostic Indicator for Recurrent Hepatocellular Carcinoma Needing Repeat Liver Resection
View abstract on PubMed
Summary
This summary is machine-generated.The albumin-bilirubin grade effectively predicts survival after repeat liver resection for recurrent hepatocellular carcinoma. Grade 1 indicates better outcomes, making these patients suitable candidates for further surgery.
Area Of Science
- Hepatobiliary surgery
- Surgical oncology
- Liver cancer research
Background
- Recurrent hepatocellular carcinoma (HCC) poses a significant challenge.
- Repeat liver resection is a treatment option for recurrent HCC.
- Predicting prognosis after repeat resection is crucial for patient selection.
Purpose Of The Study
- To evaluate the albumin-bilirubin (ALBI) grade's utility in predicting prognosis after repeat liver resection for recurrent HCC.
- To identify preoperative factors associated with survival outcomes.
Main Methods
- Retrospective analysis of 90 patients with recurrent HCC undergoing repeat liver resection (2005-2019).
- Cox proportional-hazards regression used to identify independent prognostic factors, including ALBI grade.
- Kaplan-Meier method used to compare survival between ALBI grade groups.
Main Results
- ALBI grade 2 and early recurrence (<1 year) were independently associated with poor recurrence-free survival (RFS).
- ALBI grade 2 was independently associated with poor overall survival (OS).
- Five-year RFS (31% vs. 17%) and OS (86% vs. 60%) significantly differed between ALBI grade 1 and 2 patients (p=0.003).
Conclusions
- The ALBI grade is a valuable preoperative tool for predicting survival after repeat liver resection in recurrent HCC patients.
- Patients with ALBI grade 1 demonstrate favorable survival and are better candidates for repeat liver resection.

